{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T10:43:42Z","timestamp":1770893022612,"version":"3.50.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Merck Sharpe & Dohme","award":["MISP IIS#54846"],"award-info":[{"award-number":["MISP IIS#54846"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Drug Policy"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.drugpo.2019.06.016","type":"journal-article","created":{"date-parts":[[2019,6,26]],"date-time":"2019-06-26T06:57:53Z","timestamp":1561532273000},"page":"181-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units"],"prefix":"10.1016","volume":"72","author":[{"given":"Jorge","family":"Valencia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Alvaro-Meca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Troya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Cuevas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Morro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Ca\u00f1amares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismael","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugpo.2019.06.016_bib0005","series-title":"Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection","author":"Organization WH","year":"2018"},{"issue":"12","key":"10.1016\/j.drugpo.2019.06.016_bib0010","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"The Lancet Global Health"},{"issue":"1","key":"10.1016\/j.drugpo.2019.06.016_bib0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/add.14393","article-title":"Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs","volume":"114","author":"Grebely","year":"2019","journal-title":"Addiction"},{"key":"10.1016\/j.drugpo.2019.06.016_bib0020","series-title":"Guidelines on estimating the size of populations most at risk to HIV","first-page":"51","author":"UNAIDS","year":"2010"},{"key":"10.1016\/j.drugpo.2019.06.016_bib0025","series-title":"Global hepatitis report 2017","author":"Organization WH","year":"2017"},{"issue":"1","key":"10.1016\/j.drugpo.2019.06.016_bib0030","doi-asserted-by":"crossref","first-page":"22146","DOI":"10.7448\/IAS.20.1.22146","article-title":"Elimination of HCV as a public health concern among people who inject drugs by 2030 - what will it take to get there?","volume":"20","author":"Grebely","year":"2017","journal-title":"Journal of the International AIDS Society"},{"issue":"6","key":"10.1016\/j.drugpo.2019.06.016_bib0035","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/QCO.0000000000000216","article-title":"Hepatitis C virus treatment as prevention in people who inject drugs: Testing the evidence","volume":"28","author":"Hickman","year":"2015","journal-title":"Current Opinion in Infectious Diseases"},{"issue":"5","key":"10.1016\/j.drugpo.2019.06.016_bib0040","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/COH.0000000000000179","article-title":"The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): The use of direct-acting antivirals as treatment for prevention","volume":"10","author":"Martin","year":"2015","journal-title":"Current Opinion in HIV and AIDS"},{"key":"10.1016\/j.drugpo.2019.06.016_bib0045","series-title":"The global state of harm reduction: Towards an integrated response","author":"Stoicescu","year":"2012"},{"issue":"6","key":"10.1016\/j.drugpo.2019.06.016_bib0050","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1080\/09540121.2016.1164290","article-title":"Implementation of rapid HIV and HCV testing within harm reduction programmes for people who inject drugs: A pilot study","volume":"28","author":"Fern\u00e0ndez-L\u00f3pez","year":"2016","journal-title":"AIDS Care"},{"key":"10.1016\/j.drugpo.2019.06.016_bib0055","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.12919","article-title":"Effectiveness and cost\u2010effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France","author":"Cousien","year":"2018","journal-title":"Journal of Viral Hepatitis"},{"issue":"6","key":"10.1016\/j.drugpo.2019.06.016_bib0060","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.drugpo.2013.05.005","article-title":"What is low threshold methadone maintenance treatment?","volume":"24","author":"Strike","year":"2013","journal-title":"The International Journal of Drug Policy"},{"issue":"6","key":"10.1016\/j.drugpo.2019.06.016_bib0065","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/MEG.0000000000000843","article-title":"Hepatitis C in a mobile low-threshold methadone program","volume":"29","author":"Silva","year":"2017","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"10","key":"10.1016\/j.drugpo.2019.06.016_bib0070","article-title":"HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination","volume":"13","author":"La Rosa","year":"2018","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.drugpo.2019.06.016_bib0075","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"66","author":"Liver EAfTSoT","year":"2017","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1016\/j.drugpo.2019.06.016_bib0080","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD\u2010IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","author":"Panel","year":"2015","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.drugpo.2019.06.016_bib0085","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1053\/j.gastro.2015.07.043","article-title":"Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection","volume":"149","author":"Foster","year":"2015","journal-title":"Gastroenterology"},{"issue":"20","key":"10.1016\/j.drugpo.2019.06.016_bib0090","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"The New England Journal of Medicine"},{"issue":"21","key":"10.1016\/j.drugpo.2019.06.016_bib0095","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.drugpo.2019.06.016_bib0100","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.12917","article-title":"Shortened therapy of eight weeks with paritaprevir\/ritonavir\/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection","author":"Martinello","year":"2018","journal-title":"Journal of Viral Hepatitis"},{"issue":"1","key":"10.1016\/j.drugpo.2019.06.016_bib0105","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/1756283X16671293","article-title":"Grazoprevir\/elbasvir combination therapy for HCV infection","volume":"10","author":"Vallet-Pichard","year":"2017","journal-title":"Therapeutic Advances in Gastroenterology"},{"issue":"1","key":"10.1016\/j.drugpo.2019.06.016_bib0110","first-page":"S513","article-title":"SOF\/VEL\/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy","volume":"66","author":"Grebely","year":"2017","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.drugpo.2019.06.016_bib0115","series-title":"Editors. Sofosbuvir-based direct-acting antiviral therapies for HCV in people receiving opioid substitution therapy: An analysis of phase 3 studies. Open forum infectious diseases;","author":"Grebely","year":"2018"},{"key":"10.1016\/j.drugpo.2019.06.016_bib0120","doi-asserted-by":"crossref","unstructured":"Alimohammadi A., Holeksa J., Thiam A., Truong D., Conway B., editors. Real-world efficacy of direct-acting antiviral therapy for HCV infection affecting people who inject drugs (PWID) delivered in a multidisciplinary setting. Open Forum Infectious Diseases; 2018.","DOI":"10.1093\/ofid\/ofy120"},{"issue":"11","key":"10.1016\/j.drugpo.2019.06.016_bib0125","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nrgastro.2017.106","article-title":"Direct-acting antiviral agents for HCV infection affecting people who inject drugs","volume":"14","author":"Grebely","year":"2017","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"issue":"2","key":"10.1016\/j.drugpo.2019.06.016_bib0130","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40121-017-0158-x","article-title":"Chronic hepatitis C treatment in patients with drug injection history: findings of the INTEGRATE prospective, observational study","volume":"6","author":"Robaeys","year":"2017","journal-title":"Infectious Diseases and Therapy"},{"issue":"4","key":"10.1016\/j.drugpo.2019.06.016_bib0135","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jvh.12823","article-title":"The benefits of hepatitis C virus cure: Every rose has thorns","volume":"25","author":"Salmon","year":"2018","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1016\/j.drugpo.2019.06.016_bib0140","series-title":"Guidelines for the screening, care and treatment of persons with hepatitis C infection","author":"Organization WH","year":"2014"},{"issue":"4","key":"10.1016\/j.drugpo.2019.06.016_bib0145","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/jgh.13223","article-title":"Cost\u2010effectiveness of treating chronic hepatitis C virus with direct\u2010acting antivirals in people who inject drugs in Australia","volume":"31","author":"Scott","year":"2016","journal-title":"Journal of Gastroenterology and Hepatology"},{"issue":"10","key":"10.1016\/j.drugpo.2019.06.016_bib0150","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.drugpo.2015.05.006","article-title":"Hepatitis C transmission and treatment as prevention\u2013The role of the injecting network","volume":"26","author":"Hellard","year":"2015","journal-title":"The International Journal of Drug Policy"},{"issue":"6","key":"10.1016\/j.drugpo.2019.06.016_bib0155","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/hep.27403","article-title":"The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs","volume":"60","author":"Hellard","year":"2014","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.drugpo.2019.06.016_bib0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163488","article-title":"Cost-effectiveness of hepatitis C treatment for people who inject drugs and the impact of the type of epidemic; extrapolating from Amsterdam, the Netherlands","volume":"11","author":"van Santen","year":"2016","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.drugpo.2019.06.016_bib0165","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/jvh.12666","article-title":"HCV reinfection incidence among individuals treated for recent infection","volume":"24","author":"Martinello","year":"2017","journal-title":"Journal of Viral Hepatitis"},{"issue":"5","key":"10.1016\/j.drugpo.2019.06.016_bib0170","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jhep.2018.07.025","article-title":"Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort","volume":"69","author":"Rossi","year":"2018","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1016\/j.drugpo.2019.06.016_bib0175","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","author":"Castera","year":"2005","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.drugpo.2019.06.016_bib0180","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/jvh.13035","article-title":"High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme","volume":"26","author":"Schulkind","year":"2019","journal-title":"Journal of Viral Hepatitis"},{"issue":"5","key":"10.1016\/j.drugpo.2019.06.016_bib0185","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/jvh.12686","article-title":"Editorial to Martinello et al.\u2019s HCV reinfection incidence among individuals treated for recent infection","volume":"24","author":"Ingiliz","year":"2017","journal-title":"Journal of Viral Hepatitis"},{"issue":"1","key":"10.1016\/j.drugpo.2019.06.016_bib0190","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.jhep.2016.07.012","article-title":"HCV epidemiology in high-risk groups and the risk of reinfection","volume":"65","author":"Midgard","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.drugpo.2019.06.016_bib0195","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.drugalcdep.2016.05.012","article-title":"Hepatitis C reinfection following treatment induced viral clearance among people who have injected drugs","volume":"165","author":"Weir","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.drugpo.2019.06.016_bib0200","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.jhep.2016.01.001","article-title":"Hepatitis C reinfection after sustained virological response","volume":"64","author":"Midgard","year":"2016","journal-title":"Journal of Hepatology"},{"issue":"3","key":"10.1016\/j.drugpo.2019.06.016_bib0205","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/jvh.12859","article-title":"Understanding and addressing hepatitis C reinfection in the oral direct\u2010acting antiviral era","volume":"25","author":"Falade-Nwulia","year":"2018","journal-title":"Journal of Viral Hepatitis"},{"issue":"9","key":"10.1016\/j.drugpo.2019.06.016_bib0210","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/cid\/cix126","article-title":"Risk factors for hepatitis C virus reinfection after sustained virologic response in patients coinfected with HIV","volume":"64","author":"Young","year":"2017","journal-title":"Clinical Infectious Diseases"},{"issue":"5","key":"10.1016\/j.drugpo.2019.06.016_bib0215","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jinf.2015.07.006","article-title":"Hepatitis C virus reinfection after sustained virological response in HIV-infected patients with chronic hepatitis C","volume":"71","author":"Pineda","year":"2015","journal-title":"The Journal of Infection"},{"key":"10.1016\/j.drugpo.2019.06.016_bib0220","article-title":"Reinfection by HCV following effective all-oral DAA therapy in HIV\/HCV-coinfected individuals","author":"Berenguer","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.drugpo.2019.06.016_bib0225","article-title":"High response and re\u2010infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme","author":"Schulkind","year":"2018","journal-title":"Journal of Viral Hepatitis"},{"issue":"3","key":"10.1016\/j.drugpo.2019.06.016_bib0230","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/02791072.2000.10400454","article-title":"Cessation of drug use: Impact of time in treatment","volume":"32","author":"Goldstein","year":"2000","journal-title":"Journal of Psychoactive Drugs"},{"issue":"2","key":"10.1016\/j.drugpo.2019.06.016_bib0235","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.drugalcdep.2005.11.007","article-title":"Longitudinal predictors of injection cessation and subsequent relapse among a cohort of injection drug users in Baltimore, MD, 1988\u20132000","volume":"83","author":"Shah","year":"2006","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.drugpo.2019.06.016_bib0240","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11524-015-9995-7","article-title":"Predictors of injection cessation and relapse among female sex workers who inject drugs in two Mexican-US border cities","volume":"93","author":"West","year":"2016","journal-title":"Journal of Urban Health"},{"key":"10.1016\/j.drugpo.2019.06.016_bib0245","series-title":"A pressing need for pharmacotherapy development to treat drug addiction: An editorial from a legal perspective. International review of neurobiology. 126","first-page":"15","author":"Andraka-Christou","year":"2016"},{"issue":"8","key":"10.1016\/j.drugpo.2019.06.016_bib0250","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/add.13375","article-title":"Buprenorphine+ naloxone plus naltrexone for the treatment of cocaine dependence: The Cocaine Use Reduction with Buprenorphine (CURB) study","volume":"111","author":"Ling","year":"2016","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.drugpo.2019.06.016_bib0255","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.cell.2015.07.046","article-title":"The brain on drugs: From reward to addiction","volume":"162","author":"Volkow","year":"2015","journal-title":"Cell"},{"issue":"2 Suppl 1","key":"10.1016\/j.drugpo.2019.06.016_bib0260","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/ADT.0000000000000104","article-title":"Medical and behavioral approaches to engage people who inject drugs into care for hepatitis C virus infection","volume":"16","author":"Gonzalez","year":"2017","journal-title":"Addictive Disorders & Their Treatment"},{"issue":"1","key":"10.1016\/j.drugpo.2019.06.016_bib0265","doi-asserted-by":"crossref","first-page":"22146","DOI":"10.7448\/IAS.20.1.22146","article-title":"Elimination of HCV as a public health concern among people who inject drugs by 2030\u2013What will it take to get there?","volume":"20","author":"Grebely","year":"2017","journal-title":"Journal of the International AIDS Society"},{"key":"10.1016\/j.drugpo.2019.06.016_bib0270","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.12904","article-title":"Feasibility of reaching world health organization targets for hepatitis C and the cost\u2010effectiveness of alternative strategies","author":"Wisl\u00f8ff","year":"2018","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1016\/j.drugpo.2019.06.016_bib0275","article-title":"Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia","author":"Iversen","year":"2018","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.drugpo.2019.06.016_bib0280","series-title":"Conference on Retroviruses and Opportunistic Infections","article-title":"Substantial decline in acute HCV infections among Dutch HIV+ MSM after DAA roll-out","year":"2017"},{"issue":"5","key":"10.1016\/j.drugpo.2019.06.016_bib0285","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S2468-1253(19)30082-2","article-title":"Eliminating hepatitis C in Europe","volume":"4","author":"Lazarus","year":"2019","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"10.1016\/j.drugpo.2019.06.016_bib0290","article-title":"Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs","volume":"9","author":"Platt","year":"2017","journal-title":"The Cochrane Database of Systematic Reviews"},{"issue":"Suppl 2","key":"10.1016\/j.drugpo.2019.06.016_bib0295","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1093\/cid\/cit296","article-title":"Combination interventions to prevent HCV transmission among people who inject drugs: Modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy","volume":"57","author":"Martin","year":"2013","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America."},{"key":"10.1016\/j.drugpo.2019.06.016_bib0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.sapharm.2019.04.004","article-title":"Directly observed hepatitis C treatment with opioid substitution therapy in community pharmacies: A qualitative study","author":"Gunn","year":"2019","journal-title":"Research in social & administrative pharmacy: RSAP"},{"issue":"9","key":"10.1016\/j.drugpo.2019.06.016_bib0305","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jvh.12910","article-title":"Aiming for elimination: Outcomes of a consultation pathway supporting regional general practitioners to prescribe direct-acting antiviral therapy for hepatitis C","volume":"25","author":"Wade","year":"2018","journal-title":"Journal of Viral Hepatitis"},{"key":"10.1016\/j.drugpo.2019.06.016_bib0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2019.02.011","article-title":"Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: Analysis of a global dataset","author":"Freiman","year":"2019","journal-title":"Journal of Hepatology"},{"issue":"11","key":"10.1016\/j.drugpo.2019.06.016_bib0315","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S2468-1253(18)30304-2","article-title":"Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: A systematic review and meta-analysis","volume":"3","author":"Hajarizadeh","year":"2018","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"10.1016\/j.drugpo.2019.06.016_bib0320","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drugpo.2017.08.001","article-title":"Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy","volume":"47","author":"Grebely","year":"2017","journal-title":"The International Journal of Drug Policy"},{"issue":"1","key":"10.1016\/j.drugpo.2019.06.016_bib0325","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.27366","article-title":"Concordance of sustained virological response 4, 12, and 24 weeks post\u2010treatment with sofosbuvir\u2010containing regimens for hepatitis C virus","volume":"61","author":"Yoshida","year":"2015","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.drugpo.2019.06.016_bib0330","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir\u2013Grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: A randomized trial","volume":"165","author":"Dore","year":"2016","journal-title":"Annals of Internal Medicine"}],"container-title":["International Journal of Drug Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395919301719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955395919301719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T15:00:44Z","timestamp":1566918044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955395919301719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":66,"alternative-id":["S0955395919301719"],"URL":"https:\/\/doi.org\/10.1016\/j.drugpo.2019.06.016","relation":{},"ISSN":["0955-3959"],"issn-type":[{"value":"0955-3959","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units","name":"articletitle","label":"Article Title"},{"value":"International Journal of Drug Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugpo.2019.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}